Search ADPT
Adaptive Biotechnologies Corp
Nasdaq · CIK 1478320
Last close28.35
Daily change+0.98 (3.58%)
10 Years gain-29.65%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ADPT · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
41.7Momentum
100.0Acceleration
100.0Confidence
64.0Annual Revenue9
Quarterly Revenue31
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth19.4 / 25
Quality14.9 / 25
Capital Efficiency0.0 / 20
Balance Sheet6.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators1.4 / 5
Signals
Gross margin expansionGross margin improved by 13.1974 percentage points.
Operating leverageOperating margin improved by 69.2299 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 7.1452%.
Low interest coverage · HIGHInterest coverage is -4.3229x.
Key Metrics
Revenue Growth TTM60.53%OK
Revenue CAGR 3Y14.34%OK
Gross Margin74.59%OK
Operating Margin-16.84%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y149.01%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y7.15%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $276.98M | $205.62M | -$57.12M | -$45.99M | -$48.95M | 74.24% | -20.62% | -17.67% | -38.13% | 151.72M |
| 2025 FY Dec 31, 2024 | $178.96M | $106.88M | -$162.55M | -$95.21M | -$98.88M | 59.72% | -90.83% | -55.25% | -124.46% | 147.1M |
| 2025 FY Dec 31, 2023 | $170.28M | $94.72M | -$227.04M | -$156.32M | -$167.02M | 55.63% | -133.33% | -98.09% | -194.97% | 144.38M |
| 2024 FY Dec 31, 2022 | $185.31M | $127.40M | -$200.19M | -$183.95M | -$200.29M | 68.75% | -108.03% | -108.09% | -92.41% | 142.52M |
| 2023 FY Dec 31, 2021 | $154.34M | $105.04M | -$208.97M | -$192.73M | -$254.47M | 68.06% | -135.39% | -164.87% | -107.92% | 140.35M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $295.28M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-332940, 0001193125-25-267061 |
| Revenue Growth TTM | 60.53% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-332940, 0001193125-25-267061 |
| Revenue CAGR 3Y | 14.34% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-076902 |
| Revenue CAGR 5Y | 23% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-076902 |
| Gross Profit CAGR 3Y | 17.3% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-076902 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-332940, 0001193125-25-267061 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 74.59% | Gross Profit / Revenue | OK | 0001193125-26-332940, 0001193125-25-267061 |
| Operating Margin | -16.84% | Operating Income / Revenue | OK | 0001193125-26-332940, 0001193125-25-267061 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-332940 |
| Interest Coverage | -4.32x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 4.79x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $1.85 | Revenue / Diluted Shares | OK | 0001193125-26-332940, 0001193125-25-267061 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |